| Name | Title | Contact Details |
|---|
KACE Company, based in Ashburn, VA, is a federal government contractor with over 30 years of experience in linguistics and related services. The company specializes in mission-critical services that enhance national security, public safety, and government operations. As one of the largest language services providers to the U.S. federal government, KACE employs over 1,500 people and is recognized as a Hispanic American Owned and Minority Owned business. KACE offers a range of professional services tailored to government needs, including program optimization, intelligence and analytics, and specialized language services. Their program optimization focuses on data-driven strategies to improve performance and efficiency. In intelligence and analytics, KACE extracts insights from large datasets to support various missions. Their language services encompass transcription, translation, interpretation, and language analysis, ensuring accurate communication across more than 150 languages and dialects.
Headquartered in Los Angeles, California, Manufacturers Bank is a wholly owned subsidiary of SMBC Americas Holding, Inc., a member of SMBC Group. For over 60 years, the Commercial Bank division of Manufacturers Bank has been serving middle-market and corporate businesses by providing sophisticated solutions and expertise with the personal touch of a community bank. The Commercial Bank division serves the specialized needs of middle-market and corporate businesses, franchise finance including quick service restaurants, manufacturers, wholesalers, distributors, importers, exporters, and service companies. We offer a comprehensive suite of credit, deposit and treasury management solutions including foreign exchange and trade finance. The Commercial Bank has offices in Los Angeles, Beverly Hills, Brea, Encino, Glendale, Newport Beach, San Jose, and Torrance. Member FDIC
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
BNCCORP, Inc. (OTCQB: BNCC), headquartered in Bismarck, N.D., is a registered bank holding company dedicated to providing banking and wealth management services to businesses and consumers in its local markets. The Company operates community banking and wealth management businesses in Arizona, Minnesota and North Dakota. BNC also conducts mortgage banking from locations in the Midwest. The Company offers financial products and services to meet the financial needs of its current customers, and potential customers, in the markets it serves.